<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The latest announcement is out from Vaxart ( (VXRT) ). On May 19, 2026, Vaxart issued a letter to shareholders and filed preliminary proxy materials ahead of its Annual Meeting scheduled for July 16, 2026, outlining clinical, financial and governance developments over the past year. The company urged investors to back its six board nominees in the face of a dissident slate, arguing that experienced leadership is vital as it advances its oral vaccine platform and seeks to safeguard long-term shareholder value. Management highlighted a fully enrolled Phase 2b COVID-19 trial with approximately 5,400 participants, ongoing work on a first-in-class norovirus vaccine and influenza programs that have shown promising human and preclinical data. Vaxart also detailed measures taken in 2025 and early 2026 to extend its cash runway into the second quarter of 2027, including restoring BARDA funding for its COVID-19 trial, securing a non-dilutive partnership with Dynavax, cutting costs through a 21% workforce reduction and relocation, and arranging a $25 million share purchase agreement. The company said these clinical and financial steps have positioned it for key value-inflection points, with upcoming COVID-19 trial safety data expected in the second quarter of 2026 and a primary efficacy readout anticipated in early 2027. Vaxart framed the proxy contest as a potential disruption to this strategy, emphasizing that its current board and management team have the regulatory, clinical and partnering expertise needed to navigate a challenging funding environment and transition toward a sustainable commercial model. The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page. Spark’s Take on VXRT Stock According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral. VXRT scores moderately positive, led by the financial turnaround to profitability/positive free cash flow and a strengthened balance sheet with low leverage. The earnings update adds support via partnership validation and extended runway, but execution and timing risks (BARDA-related delays, partner opt-in dependence, and contract-driven revenue) keep the score from being higher. Technically, the setup is mixed with softer near-term trend versus longer-term averages. To see Spark’s full report on VXRT stock, click here. More about Vaxart Vaxart, Inc. is a clinical-stage biotechnology company developing oral recombinant vaccines based on its proprietary Vector-Adjuvant-Antigen Standardized Technology (VAAST) delivery platform. The company targets infectious diseases including COVID-19, norovirus and influenza, positioning its oral pill vaccines as differentiated alternatives to market-leading injectable products in large, expanding vaccine markets. Average Trading Volume: 509,799 Technical Sentiment Signal: Hold Current Market Cap: $164.5M See more data about VXRT stock on TipRanks’ Stock Analysis page.</div>

VXRT

LABU

IBBQ

Vaxart (VXRT) has urged shareholders to support its board nominees amid a proxy contest, emphasizing the importance of experienced leadership for its oral vaccine platform. The company reported progress in its COVID-19 trial and other vaccine programs, while detailing financial measures to extend its cash runway. Analysts rate VXRT as a Buy with a $4.00 price target, though execution risks remain. Vaxart focuses on developing oral vaccines for infectious diseases, positioning itself against traditional injectable products.

Vaxart Urges Shareholder Support Amid Proxy Contest, Updates Pipeline